PLBD1

Across TCGA pan-cancer cohorts, PLBD1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLBD1 data layer compared with 19 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PLBD1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PLBD1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, HNSC, and COAD are the cancer types where PLBD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	III,IV	0.868	0.359	.006	17	view →
HNSC	OS	Quartile	II,III,IV	0.855	0.589	.008	17	view →
COAD	DFS	Quartile	III,IV	0.827	1.000	.027	6	view →
LUAD	DFS	Quartile	All	0.629	0.834	.025	5	view →
CCRCC	DFS	Quartile	III,IV	0.233	0.887	.038	3	view →
PDAC	DFS	Median	III,IV	0.445	0.271	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLBD1–LSCC (DFS)

Open the LSCC breakdown →